196 related articles for article (PubMed ID: 25086622)
1. p90/CIP2A mediates breast cancer cell proliferation and apoptosis.
Liu X; Peng B; Li Y; Lei N; Li W; Zhang JY
Mol Biol Rep; 2014 Nov; 41(11):7471-8. PubMed ID: 25086622
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
[TBL] [Abstract][Full Text] [Related]
3. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
4. CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis.
Fang Y; Li Z; Wang X; Zhang S
Tumour Biol; 2012 Dec; 33(6):2299-306. PubMed ID: 22923389
[TBL] [Abstract][Full Text] [Related]
5. CIP2A regulates cancer metabolism and CREB phosphorylation in non-small cell lung cancer.
Peng B; Lei N; Chai Y; Chan EK; Zhang JY
Mol Biosyst; 2015 Jan; 11(1):105-14. PubMed ID: 25325377
[TBL] [Abstract][Full Text] [Related]
6. Genistein targets the cancerous inhibitor of PP2A to induce growth inhibition and apoptosis in breast cancer cells.
Zhao Q; Zhao M; Parris AB; Xing Y; Yang X
Int J Oncol; 2016 Sep; 49(3):1203-10. PubMed ID: 27574003
[TBL] [Abstract][Full Text] [Related]
7. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
Niemelä M; Kauko O; Sihto H; Mpindi JP; Nicorici D; Pernilä P; Kallioniemi OP; Joensuu H; Hautaniemi S; Westermarck J
Oncogene; 2012 Sep; 31(39):4266-78. PubMed ID: 22249265
[TBL] [Abstract][Full Text] [Related]
8. CIP2A regulates proliferation and apoptosis of multiple myeloma cells.
Zheng Z; Qiao Z; Chen W; Gong R; Wang Y; Xu L; Ma Y; Zhang L; Lu Y; Jiang B; Li G; Dong C
Mol Med Rep; 2016 Sep; 14(3):2705-9. PubMed ID: 27484817
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth.
Liu N; He QM; Chen JW; Li YQ; Xu YF; Ren XY; Sun Y; Mai HQ; Shao JY; Jia WH; Kang TB; Zeng MS; Ma J
Mol Cancer; 2014 May; 13():111. PubMed ID: 24884612
[TBL] [Abstract][Full Text] [Related]
10. CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer.
Lei N; Peng B; Zhang JY
Oncol Rep; 2014 Oct; 32(4):1689-94. PubMed ID: 25109354
[TBL] [Abstract][Full Text] [Related]
11. Cancerous Inhibitor of PP2A Silencing Inhibits Proliferation and Promotes Apoptosis in Human Multiple Myeloma Cells.
Yang X; Zhang Y; Liu H; Lin Z
Biomed Res Int; 2016; 2016():6864135. PubMed ID: 27144172
[TBL] [Abstract][Full Text] [Related]
12. CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus.
Wang J; Huang T; Sun J; Yu Y; Liu Z; Li W; Jia J; Chen C
Med Oncol; 2014 Aug; 31(8):112. PubMed ID: 25023053
[TBL] [Abstract][Full Text] [Related]
13. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
Chen KF; Liu CY; Lin YC; Yu HC; Liu TH; Hou DR; Chen PJ; Cheng AL
Oncogene; 2010 Nov; 29(47):6257-66. PubMed ID: 20729919
[TBL] [Abstract][Full Text] [Related]
14. Expression and biological role of CIP2A in human astrocytoma.
Yi F; Ni W; Liu W; Bai J; Li W
Mol Med Rep; 2013 May; 7(5):1376-80. PubMed ID: 23467938
[TBL] [Abstract][Full Text] [Related]
15. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.
Laine A; Sihto H; Come C; Rosenfeldt MT; Zwolinska A; Niemelä M; Khanna A; Chan EK; Kähäri VM; Kellokumpu-Lehtinen PL; Sansom OJ; Evan GI; Junttila MR; Ryan KM; Marine JC; Joensuu H; Westermarck J
Cancer Discov; 2013 Feb; 3(2):182-97. PubMed ID: 23306062
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of CIP2A in estrogen depletion-resistant breast cancer cells treated with low-dose everolimus.
Nishio E; Hayashi T; Akaza M; Hisatomi Y; Hikichi M; Fujii T; Utsumi T; Harada N; Shimono Y
FEBS Open Bio; 2020 Oct; 10(10):2072-2080. PubMed ID: 32810922
[TBL] [Abstract][Full Text] [Related]
17. CIP2A silencing alleviates doxorubicin resistance in MCF7/ADR cells through activating PP2A and autophagy.
Zhu Z; Wei Z
Clin Transl Oncol; 2021 Aug; 23(8):1542-1548. PubMed ID: 33948919
[TBL] [Abstract][Full Text] [Related]
18. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
19. CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.
Gao F; Wang X; Chen S; Xu T; Wang X; Shen Y; Dong F; Zhong S; Shen Z
Oncol Rep; 2018 Nov; 40(5):2445-2454. PubMed ID: 30106121
[TBL] [Abstract][Full Text] [Related]
20. CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion.
Zhai M; Cong L; Han Y; Tu G
Tumour Biol; 2014 Feb; 35(2):1123-8. PubMed ID: 24014087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
